Meiji Seika Pharma initiates ME3241 Phase I study, inverting checkpoint blockade logic for autoimmune therapy
Meiji Seika Pharma initiates Phase I of ME3241, a PD-1 agonist antibody for autoimmune disease in Australia. Read the clinical analysis.
Pharma & Biotech
Pharma & Biotech
Novartis expands Cosentyx label to adolescents with hidradenitis suppurativa
FDA approves Novartis Cosentyx for adolescent hidradenitis suppurativa. Discover what this decision means for biologic treatment strategies.
Pharma & Biotech
Why the TACTI-004 Phase III outcome challenges assumptions about LAG-3 immune activation
Immutep Limited halts its TACTI-004 lung cancer trial after a futility analysis. Discover what the setback means for eftilagimod alfa and LAG-3 immunotherapy.
Medical Devices & Diagnostics
Firefly Neuroscience explores AI analysis of brain waves for ADHD subtype detection
Firefly Neuroscience explores EEG brain wave biomarkers for ADHD subtype detection using AI. Discover how neurodiagnostics may reshape ADHD diagnosis.
Pharma & Biotech
Aptar Pharma and COVIRIX Medical partner to develop inhaled broad-spectrum antiviral treatment
Aptar Pharma and COVIRIX Medical announce a DPI feasibility collaboration for inhaled broad-spectrum antivirals. Read the analysis.
Medical Devices & Diagnostics
Can Heru’s PretestPro replace multiple pretesting devices in one wearable exam?
Heru's PretestPro completes four ophthalmic pretests in under two minutes on a VR wearable. Explore what this means for clinic workflow and clinical validation. Read more.
Medical Devices & Diagnostics
Could nonthermal tumor ablation replace surgery for low-risk thyroid cancer? Pulse Biosciences launches feasibility study
Pulse Biosciences begins human study of nsPFA thyroid cancer treatment. Discover what this trial could mean for minimally invasive oncology.
Pharma & Biotech
Why Baseimmune’s IPF entry challenges a decade of single-target failure in pulmonary fibrosis
Baseimmune launches IPF pipeline using computational multi-pathway antigen design. Preclinical readouts due 2026-27. Discover what this means for fibrosis drug development.
Medical Devices & Diagnostics
Johnson & Johnson’s TECNIS PureSee approval highlights the evolving battle between EDOF and multifocal cataract lenses
Johnson & Johnson wins FDA approval for TECNIS PureSee IOL. Discover what this extended depth of focus cataract lens means for surgeons and patients.
Pharma & Biotech
Curatis licenses corticorelin to Neupharma in CHF 83.5m Japan deal
Curatis and Neupharma sign a CHF 83.5m Japan licensing deal for corticorelin in peritumoral brain edema. Read our analysis of what the deal means.